Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients with chronic low back pain

Spine

Volumn 41, Issue 22, 2016, Pages 1709-1717

  Konno, Shinichi ^a   Oda, Natsuko ^b   Ochiai, Toshimitsu ^b   Alev, Levent ^c  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Brief Pain Inventory; Chronic low back pain; Duloxetine; Efficacy; Japan; Placebo; Randomized clinical trial; Safety; Serotonin norepinephrine reuptake inhibitor

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BRAIN HEMORRHAGE; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; FOLLOW UP; HUMAN; INTERVERTEBRAL DISC PROTRUSION; INTERVERTEBRAL DISK DISEASE; JAPANESE (PEOPLE); LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHIC PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROLAND MORRIS DISABILITY QUESTIONNAIRE; STOMACH POLYP; TREATMENT DURATION; URETHRA STONE; CHRONIC PAIN; CLINICAL TRIAL; JAPAN; MIDDLE AGED; PAIN MEASUREMENT; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC PAIN; DOUBLE-BLIND METHOD; DULOXETINE HYDROCHLORIDE; FEMALE; FIBROMYALGIA; HUMANS; JAPAN; LOW BACK PAIN; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84970046064     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0000000000001707     Document Type: Article

References (37)

1. Fujii T, Matsudaira K. Prevalence of low back pain and factors associated with chronic disabling back pain in Japan. Eur Spine J 2013;22:432-8.
2. Yoshimura N, Muraki S, Oka T, et al. Epidemiology of low back pain: from a large scale epidemiologic survey "ROAD''. Nippon Seikei Geka Gakkai Zasshi 2010;84:437-9.
3. Nakamura M, Nishiwaki Y, Ushida T, et al. Prevalence and characteristics of chronic musculoskeletal pain in Japan: A second survey of people with or without chronic pain. J Orthop Sci 2014;19:339-50.
4. Pengel LH, Herbert RD, Mather CG, et al. Acute low back pain: systematic review of its prognosis. BMJ 2003;327:323.
5. Airaksinen O, Brox JI, Cedraschi C, et al. COST B13 Working Group on Guidelines for Chronic Low Back Pain. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006;S192-300.
6. Chou R, Huffman LH, American Pain Society. Medications for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147:505-14.
7. Japanese Orthopedic Association (JOA). Clinical Practice Guideline for the Management of Low Back Pain Nankodo Co. , Ltd. , Tokyo 2012 (in Japanese).
8. van Tulder MW, Scholten RJ, Koes BW, et al. Nonsteroidal antiinflammatory drugs for low back pain: A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 2000;25:2501-13.
9. Gor AP, Saksena M. Adverse drug reactions of nonsteroidal antiinflammatory drugs in orthopedic patients. J Pharmacol Pharmacother 2011;2:26-9.
10. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005;312:726-32.
11. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: A 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282-90.
12. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976) 2010;35:E578-85.
13. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-8.
14. Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder-placebo-and paroxetine-controlled double-blind comparative study. Jpn J Clin Psychopharmacol 2009;12:1613-34.
15. Hitoshi Yasuda, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan. J Diabetes Investig 2011;2: 132-9.
16. Murakami M, Osada K, Mizuno H, et al. A randomized, doubleblind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Res Ther 2015;17:224.
17. Uki J, Mendoza T, Cleeland CS, et al. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory-BPI-J. J Pain Symptom Manage December 1998;16: 364-73.
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33.
19. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.
20. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health; 1976;76-338.
21. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976) 1983;8:141-4.
22. Fukuhara S, editor. RDQ(Roland-Morris Disability Questionnaire) Japanese Manual. Tokyo: Iryobunkasha, 2004 (in Japanese).
23. Suzukamo Y, Fukuhara S, Kikuchi S, et al. Validation of the Japanese version of the Roland-Morris Disability Questionnaire. J Orthop Sci 2003;8:543-8.
24. Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998;51:1037-44.
25. Fukuhara S, Ware JE Jr, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998;51:1045-53.
26. Kind P. The EuroQoL instrument: An index of health-related quality of life. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1996. pp. 191-201.
27. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
28. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
29. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
30. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18.
31. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
32. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20.
33. Arnold LM, Clauw DJ, Wohlreich MM, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebocontrolled clinical trials. Prim Care Companion J Clin Psychiatry 2009;11:237-44.
34. Choy EH, Mease PJ, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol 2009;28:1035-44.
35. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60.
36. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41.
37. Robinson MJ, Edwards SE, Iyengar S, et al. Depression and pain. Front Biosci (Landmark Ed) 2009;14:5031-51.